Chardan lowered the firm’s price target on Metagenomi (MGX) to $11 from $12. The firm updated its model for Q2 financials and takes a slightly ...

Reports Q2 revenue $8.51M, consensus $7.72M. The company ended the quarter with $205.M in cash, cash equivalents, and marketable securities, which ...

Metagenomi Inc. (MGX) on Tuesday reported a loss of $19.9 million in its second quarter.

Metagenomi, Inc. (NASDAQ:MGX) just released its latest quarterly results and things are looking bullish. The results overall were credible, with revenues of US$8.5m beating expectations by 10%.

Metagenomi Reports Business Updates and First Quarter 2025 Financial Results - Nonhuman primate (NHP) study in hemophilia A demonstrated therapeutically relevant factor VIII (FVIII) activity with ...

In May 2025, the Company reported additional long-term data from its nonhuman primate (“NHP”) study that demonstrated durable and consistent FVIII activity levels through approximately 19 months. Mean ...

Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene ...

Metagenomi, Inc., with a market cap of US$52.71 million, is navigating the volatile terrain of penny stocks with its innovative gene-editing technologies. Despite being pre-revenue and ...

Metagenomi, Inc.: A Buy Rating for Pioneering Gene Editing Advancements TipRanks Mar. 5, 2024, 04:45 AM ...

On February 13, 2024, Metagenomi announced the closing of its initial public offering of 6,250,000 shares of its common stock at a price to the public of $15.00 per share. The aggregate gross ...

expand Brian Thomas, CEO of Metagenomi Inc. Todd Johnson | San Francisco Business Times By Kevin Truong – Assistant Managing Editor, San Francisco Business Times May 6, 2021 ...

Metagenomi, a start-up quietly founded by University of California, Berkeley, scientists in 2018, has raised $65 million in series A financing. The name refers to the growing field of metagenomics ...